Saturday, July 11, 2026
🇺🇸 FDA

Drug profile · INN

stro-

stro- is an FDA-listed pharmaceutical active ingredient.

NMPA: clinical trials
Patents linked 20
Pipeline programs 475
News articles 0
Drug details — stro-
Class
—
Route
—
Patents
20
Programs
475
Data quality
0.70
← All drugs Related patents Pipeline programs Drug news hub Event calendar

Quick answer

stro- is an FDA-listed pharmaceutical active ingredient.

Key facts

INN stro-

Approval history

Regional status spokes: APAC status

Authority Status Date
NMPA clinical trials —

Pipeline programs

Browse pipeline
  1. 0.9% Sodium Chloride Solution, Glenzocimab Phase 3 · PARItec · Acute ischemic stroke
  2. 1821-FSH-301 Phase 3 · Fulcrum Therapeutics · Facioscapulohumeral Muscular Dystrophy (FSHD)
  3. 2015-1949 Phase 3 · Ultragenyx UK · Eosinophilic Gastrointestinal Disorders (EGIDs)
  4. 20210096 Phase 3 · Amgen · Previously Untreated Advanced Gastric or Gastroesophageal Ju
  5. 20210098 Phase 3 · Amgen · Gastric and Gastroesophageal Junction Cancer With FGFR2b Ove
  6. 2mg Baricitinib Phase 3 · Chinese Academy of · Acute Ichemic Stroke
  7. 4045-301 Phase 3 · Sarepta Therapeutics · Patients with Duchenne Muscular Dystrophy Amenable to Exon 4
  8. 8951-CL-0301 Phase 3 · Astellas Pharma · Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenoc

Related patents

Browse patents

  1. WO 2026044005

    PARTICULES DE VAA COMPRENANT DES PEPTIDES CONTENANT RGD POUR ADMINISTRER DES CHARGES UTILES DE DYSTROPHINE

    Expires Wed Feb 21 2046 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12415794

    Pyridazinone compounds and uses thereof

    Expires Mon Sep 11 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12403203

    Muscle targeting complexes and uses thereof for treating dystrophinopathies

    Expires Mon Aug 28 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12397062

    Muscle targeting complexes and uses thereof for treating dystrophinopathies

    Expires Mon Aug 21 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12377150

    Exon skipping oligomer conjugates for muscular dystrophy

    Expires Mon Jul 31 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 12379385

    Methods of treating patients afflicted with irritable bowel syndrome, inflammatory bowel disease or chronic gastrointestinal functional disorders based on assessment of intestinal barrier function

    Expires Mon Jul 31 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 12329824

    Muscle targeting complexes and uses thereof for treating dystrophinopathies

    Expires Mon Jun 12 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 12280122

    Muscle targeting complexes and uses thereof for treating myotonic dystrophy

    Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 12275937

    Stereospecific linkages in RNA editing oligonucleotides

    Expires Mon Apr 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 12239716

    Muscle targeting complexes and uses thereof for treating dystrophinopathies

    Expires Mon Feb 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 12240833

    Pyridazinone compounds and uses thereof

    Expires Mon Feb 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 12240831

    Pyridazinone compounds and uses thereof

    Expires Mon Feb 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 12239717

    Muscle targeting complexes and uses thereof for treating dystrophinopathies

    Expires Mon Feb 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 12226489

    Compounds and methods for treating gastrointestinal disease

    Expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 12144867

    Muscle targeting complexes and uses thereof for treating dystrophinopathies

    Expires Mon Nov 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 12144868

    Muscle targeting complexes and uses thereof for treating dystrophinopathies

    Expires Mon Nov 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 12109204

    Methods for treating muscular dystrophies

    Expires Mon Oct 03 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 12102687

    Muscle targeting complexes and uses thereof for treating myotonic dystrophy

    Expires Mon Sep 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 12097263

    Muscle targeting complexes and uses thereof for treating myotonic dystrophy

    Expires Mon Sep 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 12053477

    Methods for treating pulmonary fibrosis

    Expires Mon Aug 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is stro-?

stro- is an FDA-listed pharmaceutical active ingredient.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.